Moderna Continues To Expect 2023 Covid-19 Sales Of $6B-$8B, Dependent On U.S. Vaccination Rates.
While the 2023 cost of sales remains elevated, the company is currently resizing its manufacturing footprint and supply base to accelerate gross margin expansion towards its longer-term target of 75-80%.